We’re thrilled to announce that we’ve secured our first lead investor, Biogena Group, led by Dr. Albert Schmidbauer. This represents a major milestone for our team and moves us closer to transforming how the world approaches longevity and healthspan.
Biogena’s investment is more than just financial support—it’s a partnership that reinforces our mission and accelerates our ability to deliver the world’s first fully digital supplement focused on mitochondrial health. Using our proprietary CellLight™ technology, based on photobiomodulation (PBM), we’re advancing the boundaries of longevity science. Now, with Biogena on board, we have the strategic support to scale our innovation globally.
What This Partnership Means for Us
What makes this collaboration particularly exciting is the long-term strategic development we’ve established with Biogena. Not only will their investment help us accelerate our go-to-market strategy, but they’re also assisting us in exploring new sales channels and transitioning to a subscription-based model. We’re set to officially launch by early 2025, aiming to position ourselves as leaders in the longevity and biohacking space.
The Longevity Market Is Thriving
The global longevity market is expected to reach a valuation of EUR 60 billion, growing at an impressive rate of 8.5% annually. This is the wave we’re riding. While people are living longer, it often means more years spent in declining health. At Luminous Labs, our mission is to address this challenge, beginning with the health of our cells.
Our CellLight™ technology targets mitochondrial health—enhancing cell regeneration, improving performance, and promoting longevity. Whether in clinical settings or at home, our digital supplement works safely and effectively, tailored to each person’s unique biology. This personalized approach is the future of wellness, and we’re proud to lead the charge.
Advancing Female Longevity
One area we’re particularly passionate about is women’s reproductive health. The female reproductive system ages faster than any other part of the body, and we’re focusing on how CellLight™ can optimize IVF treatments and support women during menopause.
In collaboration with a leading Austrian fertility clinic, our early trials have shown encouraging results, positioning us to significantly enhance female longevity. This is just the beginning—we plan to extend this success to improve longevity for all, shaping the future of healthcare.
What’s Next for Us?
One of our most exciting collaborations is with a renowned German premium car manufacturer. While details remain under wraps, this partnership represents a bold new direction for Luminous Labs. Imagine our CellLight™ technology integrated into future mobility systems—creating environments that promote health and wellness even on the go. This showcases just how versatile and impactful our technology can be.
A Pivotal Moment in Our Journey
The timing of this seed round couldn’t be more strategic. We’ve been invited back to the prestigious Longevity Investors Conference in Gstaad, where last year we were one of only seven startups selected to showcase our technology—and the only one to do so while fully bootstrapped. Now, with Biogena’s support, we’re entering this conference at a crucial stage in our journey, ready to close the seed round swiftly and take the next step toward redefining health and wellness.
As Barbara Sekulovska, one of our co-founders, shares: “Momentum is building, and we feel the anticipation. With slots in the seed round rapidly filling up, the chance to join this groundbreaking journey is closing quickly.”
In Conclusion
We’re incredibly excited about what lies ahead for Luminous Labs. With Biogena’s investment and our ongoing collaborations, we’re poised to make a significant impact on the global health market. Our goal is simple yet profound: to extend human healthspan through light and technology, empowering people to live longer, healthier lives.
This journey has just begun, and we can’t wait to bring you along for the ride. The future of health is bright, and we’re leading the way.
